Azenta shares jumped about 21% on Wednesday, the day after the life sciences company reported quarterly results and an outlook that beat Wall Street forecasts. The stock closed at $48.90, up $8.42 from Tuesday’s close of $40.48, after trading as high as about $50 during the session.
For its fiscal fourth quarter, which ended Sept. 30, Azenta reported revenue of $167 million, up 5% from a year earlier, and adjusted earnings of 28 cents a share, up from 21 cents. Analysts had expected 11 cents a share on revenue of $160.2 million, according to FactSet estimates cited by CNBC.
The Burlington, Massachusetts, company, which stores biological samples and provides genetic sequencing for drug makers and research institutions, said it expects revenue of $648 million to $660 million in fiscal 2027, above the $639.2 million analysts had forecast, according to CNBC. It also expects organic revenue growth of 3% to 5% and an adjusted EBITDA margin about 2 to 2.5 percentage points wider than in fiscal 2026.
“Fiscal 2027 is about consistent execution and accelerating performance,” interim Chief Executive Martin Madaus said in the company’s results release.
…
That’s the story. … Thank you for listening to Cedar Global Markets. We’re supported by our partners, and you can learn more about the partner featured on this page. We’ll see you next time.
